US Patent

US11311541 — Treatment of GVHD

Method of Use · Assigned to Kadmon Corp LLC · Expires 2035-04-09 · 9y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating graft versus host disease (GVHD), including chronic GVHD, using compounds that inhibit ROCK2.

USPTO Abstract

The invention relates to treatment of graft versus host disease (GVHD) using compounds that inhibit ROCK2. In preferred aspects, the present invention provides methods for the treatment of GVHD, including chronic GVHD (cGVHD) using compounds having the formulae 1-XXV, as set forth herein.

Drugs covered by this patent

belumosudil-mesylate (BELUMOSUDIL MESYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3369`	—	belumosudil-mesylate

Patent Metadata

Patent number: US11311541
Jurisdiction: US
Classification: Method of Use
Expires: 2035-04-09
Drug substance claim: No
Drug product claim: No
Assignee: Kadmon Corp LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.